Skip to content
Search

Latest Stories

GPhC takes action against 36 pharmacy premises over codeine linctus sales

The General Pharmaceutical Council (GPhC) has so far taken serious enforcement action against 36 pharmacy premises and a pharmacy professional after investigations revealed unusual high sales of codeine linctus.

The council initiated this process in July 2020.


Codeine linctus is classified as a Pharmacy (P) medicine under the Medicines Act 1968 and the Human Medicines Regulations 2012 which allows it to be sold only under a pharmacist’s supervision, by a pharmacy, without prescription.

The medicine, occasionally used for a dry cough, is high risk because of known problems associated with its misuse, abuse or overuse.

The investigation found that pharmacies involved did not properly identify and manage the risks related to obtaining or selling codeine linctus, GPhC said in a statement.

“Our unannounced inspections identified that appropriate safeguards were not always in place to ensure sales were managed safely and appropriately. There were often insufficient controls to prevent repeat sales or to identify trends in requests. In some cases, repeat sales were even made knowingly to the same people,” it said.

After the inspections, the offending pharmacies had conditions put on their registration that they “must not sell or supply any codeine linctus preparations” without an NHS prescription.

Besides, a warning has been issued to the superintendent pharmacist and regular responsible pharmacist of one of the pharmacies involved, who were found to have allowed the supply of codeine linctus without sufficient checks.

Claire Bryce-Smith, Director of Insight, Intelligence and Inspection said: “Opioids are a high-risk medicine with potential for abuse. We know that across Great Britain most pharmacies and professionals have appropriate safeguards in place in order to prevent them being misused and to provide patients with safe patient-centred care. Over the course of one year we have taken swift and robust action against 36 pharmacies and a superintendent pharmacist who were found not to have these safeguards in place.

“People requesting codeine linctus can be well-rehearsed, believable or aggressive and will often exploit shift patterns, relying on poor handover or communication between shifts. We are asking pharmacy owners and professionals to remain vigilant and ensure controls are in place to prevent repeat sales or to identify trends in requests.”

More For You

GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less
Community Pharmacy Scotland secures £10m reimbursement uplift amid ongoing negotiations

Negotiations continue on the Global Sum element of remuneration.

Getty Images

Community Pharmacy Scotland secures £120m reimbursement deal for 2025/26

Community Pharmacy Scotland (CPS) has accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

The agreement marks the first phase of ongoing negotiations surrounding community pharmacy funding for the upcoming financial year.

Keep ReadingShow less